Novartis v. Alembic & Natco: ENTRESTO Patent Infringement Ends in Consent Judgment
Novartis AG secured a consent judgment and order of injunction against Alembic entities in a Delaware District Court action protecting four patents covering ENTRESTO® (sacubitril/valsartan) heart failure tablets. The case ran for 1,567 days before resolving without a merits trial, blocking generic entry for the Alembic defendants.
ENTRESTO® patent block: Novartis locks out Alembic via consent judgment
On 24 October 2019, Novartis AG filed a patent infringement action in the District of Delaware (Case No. 1:19-cv-02021) against Alembic and a group of defendants including Natco Pharma Limited, Natco Pharma Inc., Alembic Global Holding SA, Alembic Pharmaceuticals Inc., Macleods Pharma USA Inc., and Macleods Pharmaceuticals Ltd. The suit asserted four US patents — US8101659B2, US9388134B2, US8796331B2, and US8877938B2 — covering ENTRESTO® tablets (sacubitril/valsartan) in all three approved strengths: 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg.
The case resolved on 7 February 2024 when Judge Richard G. Andrews signed a Consent Judgment and Order of Injunction between Novartis and the Alembic defendants (Alembic Global Holding SA, Alembic Pharmaceuticals Limited, and Alembic Pharmaceuticals Inc.). A consent judgment is a negotiated, court-entered resolution carrying the legal force of a final judgment; the accompanying injunction order means the Alembic entities are formally barred from manufacturing, selling, or offering their generic sacubitril/valsartan products in the US without Novartis’s authorisation. This is the termination basis recorded for the case.
At 1,567 days, the case lasted over four years — longer than the median Hatch-Waxman ANDA litigation, though not unusual for complex multi-defendant pharmaceutical patent disputes. The consent judgment, entered without a trial on the merits, suggests the parties reached a negotiated resolution whose specific terms — including any authorised generic or market entry date — are not fully disclosed in the public docket. The positions of co-defendants Natco Pharma and Macleods entities relative to this consent judgment are not specified in the available public record.
Filing to settlement in 1567 days
1,567 days — over 4 years from filing to consent judgment
Consent Judgment and Injunction: what it means for both parties
What a consent judgment means in ANDA patent litigation
A consent judgment is a binding court order agreed to by both parties — it carries the full legal weight of a litigated judgment without requiring a trial. In Hatch-Waxman ANDA cases, consent judgments typically reflect a negotiated resolution in which the generic defendant agrees not to launch before a specified date. The injunction component here formally prevents the Alembic defendants from commercialising their sacubitril/valsartan ANDA products without authorisation.
Binding — no further appeal on meritsNovartis secures IP protection without trial risk
By obtaining a consent judgment and injunction rather than proceeding to trial, Novartis avoids any judicial ruling that could have invalidated or narrowed one or more of its four asserted patents. ENTRESTO® generated multi-billion dollar annual revenues for Novartis, making patent protection highly commercially significant. A consent outcome preserves the patents’ validity on the public record and sets a precedent that may deter other generic challengers from contesting the same claims.
Patents intact — no validity rulingAlembic entities are injuncted; Natco and Macleods positions unclear
The consent judgment names Alembic Global Holding SA, Alembic Pharmaceuticals Limited, and Alembic Pharmaceuticals Inc. as the bound parties. The public record does not specify whether Natco Pharma or Macleods entities resolved separately, are still bound by related proceedings in the MDL (1:20-md-02930-RGA), or reached independent agreements. Practitioners monitoring generic entry timelines for sacubitril/valsartan should verify the status of all co-defendants in the associated MDL docket.
Natco/Macleods status — check MDL docketPart of a broader MDL — four related case numbers
The consent order references four associated case numbers, including the consolidated MDL 1:20-md-02930-RGA. Multi-district litigation consolidation in ANDA cases typically groups parallel infringement actions against multiple generic filers before a single judge for pre-trial efficiency. The MDL structure suggests Novartis pursued enforcement against multiple ANDA filers simultaneously. Resolution in this case does not necessarily bind parties in the MDL who were not named in this specific consent judgment.
MDL: 1:20-md-02930-RGAFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novartis, AG | Company | Novartis AG — global pharmaceutical company, holder of ENTRESTO® (sacubitril/valsartan) patentsSearch in Eureka ↗ |
| Defendant | Alembic | Company | Alembic, Natco Pharma, and Macleods — generic pharmaceutical manufacturers seeking ANDA approvalSearch in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Christina Schwarz | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Deanne E. Maynard | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Jared L. Stringham | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Melinda R. Roberts | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Nicholas N. Kallas | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Whitney M. Howard | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Defendant counsel | Amit Singhai | Attorney | Counsel for AlembicSearch in Eureka ↗ |
| Defendant counsel | Eve H. Ormerod | Attorney | Counsel for AlembicSearch in Eureka ↗ |
| Defendant counsel | Frank D. Rodriguez | Attorney | Counsel for AlembicSearch in Eureka ↗ |
| Defendant counsel | Helena C. Rychlicki | Attorney | Counsel for AlembicSearch in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Chief Judge | Delaware District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The Consent Judgment and Order of Injunction, signed by Judge Andrews on 7 February 2024, constitutes a final, court-entered resolution binding specifically on Alembic Global Holding SA, Alembic Pharmaceuticals Limited, and Alembic Pharmaceuticals Inc. The injunction component carries immediate legal effect: the named Alembic entities cannot commercialise their sacubitril/valsartan ANDA products in the US without Novartis’s authorisation. Critically, the order does not constitute a judicial finding on patent validity or infringement — the patents remain unchallenged on the merits. The associated MDL and related case references indicate that this resolution is one of several coordinated enforcement actions, and other defendants’ positions remain separately governed.
US8101659B2 and three further patents — sacubitril/valsartan heart failure therapy
The four patents at issue — US8101659B2, US9388134B2, US8796331B2, and US8877938B2 — form part of Novartis’s intellectual property estate protecting ENTRESTO® (sacubitril/valsartan), the first approved angiotensin receptor–neprilysin inhibitor (ARNi) for heart failure with reduced ejection fraction. The patents span application dates across multiple prosecution windows (application numbers US12/147570, US14/311788, US13/687659, and US11/722360), consistent with a layered filing strategy covering the compound, synthesis routes, and formulation aspects of this novel drug combination.
ENTRESTO® represents one of the most commercially significant cardiovascular drug launches of the past decade, generating over $3 billion annually for Novartis at peak revenues. A four-patent portfolio assertable against any ANDA filer creates a formidable barrier to generic entry: each patent must be independently overcome, and patent term extensions under 35 U.S.C. § 156 may further extend exclusivity beyond nominal expiry. For competitors in the cardiovascular formulation space, this estate signals that compound, synthesis, and formulation claims were all pursued in parallel — a model increasingly used to extend de facto exclusivity on blockbuster small-molecule drugs.
Should you run an FTO against the ENTRESTO® sacubitril/valsartan patent estate?
Any pharmaceutical company developing a sacubitril/valsartan generic, a related ARNi combination, or a novel neprilysin inhibitor compound should treat an FTO analysis of this four-patent estate as essential prior to IND filing or ANDA submission. The patents cover multiple layers — compound, synthesis, and formulation — meaning a design-around of one patent may not clear the path against the others. R&D teams should map their proposed synthesis route and final formulation against the claims of all four US patents before committing manufacturing investment.
PatSnap Eureka’s FTO Search Agent can map your compound structure and synthesis pathway against the claim scope of US8101659B2, US9388134B2, US8796331B2, and US8877938B2 simultaneously, flagging freedom-to-operate risks at the claim level. Eureka’s patent monitoring tools can also alert your team to any continuation applications, patent term extension filings, or new assertions in the MDL docket — giving product teams and IP counsel the earliest possible warning of emerging exclusivity risk in the sacubitril/valsartan space.
Run a freedom-to-operate analysis on US8101659B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent litigation: sacubitril/valsartan and cardiovascular ARNi cases
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the cardiovascular pharma IP landscape
Novartis’s consent judgment outcome reinforces that ENTRESTO® remains a strongly defended patent estate — and signals how Hatch-Waxman enforcement plays out for high-revenue biologics-adjacent products.
Consent judgments in ANDA cases are a signal of negotiating strength, not weakness
When a branded pharmaceutical company secures a consent judgment with injunction rather than settling for a launch date, it typically signals confidence in the patent portfolio. Generic defendants who agree to injunctions without trial usually do so because the litigation risk — including potential for a finding of willful infringement — outweighs the commercial upside of continued litigation. For IP strategists, this outcome suggests Novartis’s four-patent estate presented a credible blocking position.
Four-patent stacking increases the cost of generic challenge
Asserting four patents across a single ANDA product forces generic challengers to invalidate or design around all of them. US8101659B2, US9388134B2, US8796331B2, and US8877938B2 collectively cover multiple aspects of the sacubitril/valsartan composition and synthesis. This layered patent strategy — common in blockbuster pharmaceutical portfolios — raises the litigation cost and risk for generics, making early consent judgments more likely. R&D teams developing formulation alternatives should map all four claims before committing to a product pathway.
Novartis v Alembic — key questions answered
The case resolved on 7 February 2024 via a Consent Judgment and Order of Injunction entered by Judge Richard G. Andrews. The judgment was entered against Alembic Global Holding SA, Alembic Pharmaceuticals Limited, and Alembic Pharmaceuticals Inc., barring them from commercialising generic sacubitril/valsartan products without Novartis’s authorisation.
Novartis asserted four US patents: US8101659B2 (App. No. US12/147570), US9388134B2 (App. No. US14/311788), US8796331B2 (App. No. US13/687659), and US8877938B2 (App. No. US11/722360). All four cover aspects of sacubitril/valsartan, the active combination in ENTRESTO® tablets across all three approved strengths.
A consent judgment is a binding court order agreed to by both parties without a trial on the merits. In ANDA patent cases, it typically includes an injunction preventing the generic defendant from launching until a specified date or patent expiry. The specific market entry date agreed in this case is not disclosed in the public docket, so generic entry timing for Alembic’s sacubitril/valsartan product requires direct docket review.
The MDL 1:20-md-02930-RGA is a multi-district litigation consolidation that groups related ENTRESTO® ANDA infringement cases before Judge Andrews in Delaware for pre-trial efficiency. Case 1:19-cv-02021 is one of at least four associated cases. The consent judgment in this case binds the named Alembic defendants but does not necessarily resolve the positions of Natco Pharma or Macleods entities, whose status in the MDL should be checked separately.
The Order of Injunction entered on 7 February 2024 prohibits the named Alembic defendants — Alembic Global Holding SA, Alembic Pharmaceuticals Limited, and Alembic Pharmaceuticals Inc. — from manufacturing, selling, offering to sell, or importing their generic sacubitril/valsartan ANDA products in the United States without Novartis’s authorisation. The precise scope and duration of the injunction as recorded publicly is consistent with standard Hatch-Waxman consent judgments.
PatSnap Eureka searches patents and litigation data to answer instantly.